Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00257959 |
Recruitment Status :
Completed
First Posted : November 24, 2005
Last Update Posted : July 27, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ventricular Tachycardia | Drug: amiodarone beta blocker sotalol | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Study Start Date : | January 2001 |
Study Completion Date : | October 2004 |

- ICD shock for any cause

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: spontaneous or inducible ventricular tachycardia or fibrillation -
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257959
Canada, Ontario | |
McMaster University | |
Hamilton, Ontario, Canada |
Principal Investigator: | Stuart Connolly | McMaster University |
ClinicalTrials.gov Identifier: | NCT00257959 |
Other Study ID Numbers: |
1 |
First Posted: | November 24, 2005 Key Record Dates |
Last Update Posted: | July 27, 2006 |
Last Verified: | November 2005 |
Tachycardia Tachycardia, Ventricular Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Cardiac Conduction System Disease Pathologic Processes Amiodarone Sotalol Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
Anti-Arrhythmia Agents Vasodilator Agents Potassium Channel Blockers Membrane Transport Modulators Sodium Channel Blockers Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP3A Inhibitors Sympatholytics Autonomic Agents Peripheral Nervous System Agents |